HomeCompareATVI vs PFE

ATVI vs PFE: Dividend Comparison 2026

ATVI yields 1.05% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATVI wins by $21.9K in total portfolio value
10 years
ATVI
ATVI
● Live price
1.05%
Share price
$94.42
Annual div
$0.99
5Y div CAGR
56.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$71.5K
Annual income
$22,936.56
Full ATVI calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — ATVI vs PFE

📍 ATVI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATVIPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATVI + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATVI pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATVI
Annual income on $10K today (after 15% tax)
$89.12/yr
After 10yr DRIP, annual income (after tax)
$19,496.08/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $2,823.83/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATVI + PFE for your $10,000?

ATVI: 50%PFE: 50%
100% PFE50/50100% ATVI
Portfolio after 10yr
$60.5K
Annual income
$24,597.64/yr
Blended yield
40.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ATVI right now

ATVI
Analyst Ratings
36
Buy
24
Hold
Consensus: Buy
Price Target
$93.88
-0.6% upside vs current
Range: $77.00 — $116.00
Altman Z
7.6
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATVI buys
8
PFE buys
0
PoliticianChamberTickerTypeAmountDate
Richard W. Allen🏢 House$ATVI▼ Sell$1,001 - $15,0002023-10-13
Richard W. Allen🏢 House$ATVI▼ Sell$15,001 - $50,0002023-10-13
Ro Khanna🏢 House$ATVI▲ Buy$1,001 - $15,0002023-10-10
Seth Moulton🏢 House$ATVI▼ Sell$500,001 - $1,000,0002023-08-18
Seth Moulton🏢 House$ATVI▼ Sell$50,001 - $100,0002023-08-18
Ro Khanna🏢 House$ATVI▲ Buy$1,001 - $15,0002023-06-26
Seth Moulton🏢 House$ATVI▼ Sell$100,001 - $250,0002023-06-13
Ro Khanna🏢 House$ATVI▼ Sell$15,001 - $50,0002023-05-23
Tommy Tuberville🏛 Senate$ATVI▼ Sell$100,001 - $250,0002023-04-26
Tommy Tuberville🏛 Senate$ATVI▼ Sell$100,001 - $250,0002023-04-26
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATVIPFE
Forward yield1.05%6.13%
Annual dividend / share$0.99$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR56.6%13.2%
Portfolio after 10y$71.5K$49.6K
Annual income after 10y$22,936.56$26,258.71
Total dividends collected$47.5K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold
Analyst price target$93.88$27.50

Year-by-year: ATVI vs PFE ($10,000, DRIP)

YearATVI PortfolioATVI Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$10,864$164.20$9,153$693.39+$1.7KATVI
2$11,886$261.08$8,593$849.25+$3.3KATVI
3$13,136$418.03$8,336$1,066.78+$4.8KATVI
4$14,731$676.15$8,437$1,384.80+$6.3KATVI
5$16,872$1,109.79$9,013$1,875.40+$7.9KATVI
6$19,914$1,860.29$10,306$2,680.72+$9.6KATVI
7$24,521$3,213.40$12,820$4,101.38+$11.7KATVI
8$32,029$5,791.09$17,673$6,826.70+$14.4KATVI
9$45,341$11,070.49$27,543$12,591.86+$17.8KATVI
10$71,452$22,936.56$49,560$26,258.71+$21.9KATVI

ATVI vs PFE: Complete Analysis 2026

ATVIStock

Activision Blizzard, Inc., together with its subsidiaries, develops and publishes interactive entertainment content and services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through three segments: Activision, Blizzard, and King. It develops and distributes content and services on video game consoles, personal computers, and mobile devices, including subscription, full-game, and in-game sales, as well as by licensing software to third-party or related-party companies that distribute Activision and Blizzard products. The company also maintains a proprietary online gaming service, Battle.net that facilitates digital distribution of content, online social connectivity, and the creation of user-generated content. In addition, it operates esports leagues and offer digital advertising content; and provides warehousing, logistics, and sales distribution services to third-party publishers of interactive entertainment software, as well as manufacturers of interactive entertainment hardware products. The company's key product franchises include Call of Duty, World of Warcraft, Diablo, Hearthstone, Overwatch, Overwatch League, and Candy Crush. It serves retailers and distributors, including mass-market retailers, consumer electronics stores, discount warehouses, and game specialty stores through third-party distribution and licensing arrangements. The company is headquartered in Santa Monica, California.

Full ATVI Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ATVI vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATVI vs SCHDATVI vs JEPIATVI vs OATVI vs KOATVI vs MAINATVI vs JNJATVI vs MRKATVI vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.